Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Moderna (NASDAQ:MRNA) on Friday, setting a price target of $188, which is approximately 4.71% above the present share price of $179.54.
Livshits expects Moderna to post earnings per share (EPS) of $3.05 for the second quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Moderna, with an average price target of $190.22.
The analysts price targets range from a high of $231 to a low of $100.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.94 billion and a net profit of $1.27 billion. The company's market cap is $72.09 billion.
According to TipRanks.com, Chardan Capital analyst Geulah Livshits is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 68.0% and a 67.92% success rate.
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.